Varying strategies among managed care organizations for PCSK9 inhibitors will shape the care of high-risk cardiovascular patients.
Matt Jarvis, PharmD
Advertisement
Articles by Matt Jarvis, PharmD
Advertisement
Latest Updated Articles
PCSK9 Inhibitors: Who are the Best Candidates for Therapy?August 16th 2016
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Beyond Injections: The Rise of Oral GLP-1 Therapy
3
FAQs Amid the Ongoing US Measles Outbreaks
4
GLP-1 Reimbursement Crisis: What Independent Pharmacies Need to Know About Staying Viable
5